| Dr Patrick Michael O'connor, MD, MPH | |
|
6172 Strasburg Rd, Gap, PA 17527-9022 | |
| (215) 400-0083 | |
| Not Available |
| Full Name | Dr Patrick Michael O'connor |
|---|---|
| Gender | Male |
| Speciality | Preventive Medicine - Public Health & General Preventive Medicine |
| Location | 6172 Strasburg Rd, Gap, Pennsylvania |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1912143850 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2083P0901X | Preventive Medicine - Public Health & General Preventive Medicine | MD435013 (Pennsylvania) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Patrick Michael O'connor, MD, MPH 6172 Strasburg Rd, Gap, PA 17527-9022 Ph: (215) 400-0083 | Dr Patrick Michael O'connor, MD, MPH 6172 Strasburg Rd, Gap, PA 17527-9022 Ph: (215) 400-0083 |
News Archive
Simcere Pharmaceutical Group, a leading manufacturer and supplier of branded generic pharmaceuticals and manufacturer of the patented anti-cancer biotech product Endostar (also known as Endu) in China, announced today the successful completion of Endostar Phase IV clinical study at a conference in Beijing dedicated to this study.
A new study, released today in the scientific journal Advances in Therapy is providing critical evidence that neurotechnology combined with saliva testing can drastically reduce the likelihood of falsely determining cannabis impairment due to THC residual detection.
The risk of infection of COVID-19 is high for medical specialists who come in contact with symptomatic or asymptomatic patients.
The number of oral cancer cases diagnosed each year in the UK has risen above 6,000 for the first time, new figures from Cancer Research UK show today.
A synthetic, soft tissue retina developed by an Oxford University student could offer fresh hope to visually impaired people.
› Verified 5 days ago